Abstract 3957
Background
Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy associated with dismal prognosis. In order to support diagnosis and to risk stratify patients, more reliable biomarkers are urgently needed. Emerging evidence suggests a functional role of transforming growth factor-β (TGF-β) in MPM tumorigenesis, however, its clinical implementation remains unknown.
Methods
Pleural effusion samples from 48 consecutively diagnosed MPM patients and 24 patients with non-malignant pleural disease (NMPD) at diagnosis were measured by ELISA for TGF-β and by chemiluminescence enzyme immunoassay for mesothelin (SMRP). In 22 of those MPM and 19 of those NMPD patients, TGF-β and SMRP were also measured in corresponding sera.
Results
Effusion TGF-β levels were significantly higher in MPM patients than in NMPD patients (p < 0.0001), with an AUC of 0.78 (p = 0.0001). Both epithelioid and non-epithelioid MPM patients had significantly higher effusion TGF-β levels than NMPD patients (NMPD vs epithelioid: p < 0.05; NMPD vs non-epithelioid: p < 0.0001) and within the MPM patient cohort elevated effusion TGF-β levels were seen in patients with advanced disease (p < 0.005). Strikingly, patients with high effusion TGF-β levels ( > =14.36ng/mL) had significantly worse overall survival (HR 3.30, p < 0.0005) which was confirmed by a multivariate cox regression model yielding effusion TGF-β and multimodality treatment to be independently prognostic. In contrary, circulating TGF-β was neither diagnostic nor prognostic and did not correlate with matched effusion TGF-β. Of note, effusion SMRP performed similar to effusion TGF-β as diagnostic marker (AUC: 0.71, p = 0.005), but was only elevated in epithelioid tumors and not prognostic in our MPM cohort. However, there was a significant negative correlation between effusion TGF-β and SMRP and by combining both biomarkers we could remarkably increase sensitivity to 93.4%.
Conclusions
Our data is the first evidence showing pleural effusion TGF-β to be a novel highly diagnostic and prognostic biomarker in MPM applicable for epithelioid and non-epithelioid MPM. Those findings may pave the way for future clinical trials targeting TGF-β in MPM and beyond.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Langer: Full / Part-time employment, Employed at Fujirebio Germany, which provided non-financial support in terms of SMRP measurements: Fujirebio Germany GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract